.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Update on Systemic Therapy for Advanced Liver Cancer

EP. 1: Newly Diagnosed Advanced HCC: Frontline Therapy Overview

December 2nd 2019

EP. 2: Selecting a Frontline TKI for Advanced HCC

December 2nd 2019

EP. 3: Frontline I/O Therapy for HCC: Results From CheckMate459

December 2nd 2019

EP. 4: Advanced HCC: Trial Data for Frontline Combination Therapy

December 2nd 2019

EP. 5: Future of Frontline Combination Therapy in Advanced HCC

December 2nd 2019

EP. 6: Second-Line Therapy for Advanced HCC: The RESOURCE Trial

December 2nd 2019

EP. 7: Second-Line Therapy for Advanced HCC: The CELESTIAL Trial

December 2nd 2019

EP. 8: Second-Line Use of I/O Therapy for Advanced HCC

December 2nd 2019

EP. 9: Advanced HCC: Guiding Second-Line Therapy With AFP

December 2nd 2019

EP. 10: Evolving HCC Treatment Paradigm: Combinations and Sequencing

December 2nd 2019